KIN-3248
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for KIN-3248, covering 2025-05-07 to 2025-05-07. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations [Phase 1]